Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof

Patent metadata

Field	Value
Publication number	US-9428554-B2
Application number	US-43349709-A
Country	US
Kind code	B2
Filing date	Apr 30, 2009
Priority date	Nov 8, 2001
Publication date	Aug 30, 2016
Grant date	Aug 30, 2016

Abstract

The present invention relates to monoclonal antibody specifically binding to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF2 or its conserved variants or its active fragments, or other monoclonal antibodies against ORF2 which can cross react with said monoclonal antibody of present invention, and its nucleotide sequence or its degenerate sequence; to the antigenic determinant in hepatitis E virus ORF2; to a method for screening isolated or recombined polypeptide or polypeptide analog, which has the same property of specifically binding said monoclonal antibody 8C11 and/or 8H3 as said antigenic determinant 1) or 3) of hepatitis E virus ORF2; to polypeptide or polypeptide analog screened by the method above and its nucleotide sequence or degenerate sequence; to a use of said polypeptide or polypeptide analog in preparation of a medicament for the diagnosis and/or precaution of hepatitis E virus infection; to a diagnostic kit for hepatitis E virus infection and a vaccine composition for prophylaxis of hepatitis E virus infection; to use of said monoclonal antibodies or their active fragments or conserved variants in preparation of a medicament for diagnosis, prophylaxis and/or treatment of hepatitis E virus infection; to pharmaceutical composition for prophylaxis and/or treatment of hepatitis E virus infection and a method for prophylaxis and/or treatment of hepatitis E virus infection; to a recombinant expression vector comprising said nucleotide molecule in present invention and a host cell transformed with said recombinant expression vector that is able to express monoclonal antibody and its conserved variants or active fragments or polypeptide or polypeptide analogs.

First claim

What is claimed is:

1. An isolated or recombinant polypeptide which is:
1) polypeptide 239 consisting of amino acid sequence as set forth in SEQ ID NO:21;
2) polypeptide 243 consisting of amino acid sequence as set forth in SEQ ID NO:23;
3) polypeptide 251 consisting of amino acid sequence as set forth in SEQ ID NO:24;
4) polypeptide 262 consisting of amino acid sequence as set forth in SEQ ID NO:25; or
5) polypeptide 292 consisting of amino acid sequence as set forth in SEQ ID NO:26.

2. An isolated or recombined polypeptide according to claim 1 , for use in prophylaxis and/or treatment of hepatitis E virus infection, wherein the polypeptide is polypeptide 239 consisting of an amino acid sequence as set forth in SEQ ID NO:21.

3. A nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide according to claim 1 .

4. A recombinant expression vector comprising a nucleic acid molecule according to claim 3 .

5. An isolated host cell transformed with the recombinant expression vector according to claim 4 , which is able to express the isolated or recombinant polypeptide.

6. A method of detecting a hepatitis E virus infection comprising providing a sample from a subject suspected of infection, contacting the polypeptide of claim 1 with the sample, and detecting binding of the polypeptide to an antibody against the infection in the sample.

7. A method for prophylaxis or treatment of hepatitis E virus infection in a subject, comprising administering to the subject an effective amount of the isolated or recombinant polypeptide according to claim 1 , wherein the polypeptide is polypeptide 239 consisting of an amino acid sequence as set forth in SEQ ID NO:21.

8. A kit for detecting hepatitis E virus infection, which comprises at least one isolated or recombinant polypeptide selected from the group consisting of 1) polypeptide 239 consisting of amino acid sequence as set forth in SEQ ID NO:21, 2) polypeptide 243 consisting of amino acid sequence as set forth in SEQ ID NO:23, 3) polypeptide 251 consisting of amino acid sequence as set forth in SEQ ID NO:24, 4) polypeptide 262 consisting of amino acid sequence as set forth in SEQ ID NO:25, and 5) polypeptide 292 consisting of amino acid sequence as set forth in SEQ ID NO:26; and a detection agent suitable for detecting reaction between said polypeptide and an antibody.

9. The kit of claim 8 , wherein, 1) said kit is useful for detection of antibody IgG against hepatitis E virus in a sample; or 2) said kit is useful for detection of antibody IgM against hepatitis E virus in a sample; or 3) said kit is useful for detection of total antibody against hepatitis E virus in a sample.

10. A vaccine composition for prophylaxis of hepatitis E virus infection, which comprises an immunologically effective amount of polypeptide 239 consisting of amino acid sequence as set forth in SEQ ID NO:21.

11. The composition of claim 10 , wherein the immunologically effective amount is 0.0001 mg-0.1 mg per administration.

12. The composition of claim 10 , wherein the immunologically effective amount is 0.01 mg-0.04 mg per administration.

13. A pharmaceutical composition for prophylaxis and/or treatment of hepatitis E virus infection, which comprises treatment effective amount of polypeptide 239 consisting of amino acid sequence as set forth in SEQ ID NO:21 and a pharmaceutically acceptable vehicle and/or excipient.

14. The composition of claim 13 , wherein the treatment effective amount is 0.001 mg-20 mg per kilogram of body weight.

15. The composition of claim 13 , wherein the treatment effective amount is 0.1 mg-10 mg/kg per kilogram of body weight.

Assignees

• Xia Ningshao
• Zhang Jun
• Gu Ying
• Li Shaowei
• Ge Shengxiang
• He Zhiqiang
• Univ Xiamen
• Beijing Wantai Biological Pharmacy Entpr Co Ltd

Inventors

• Xia Ningshao
• Zhang Jun
• Gu Ying
• Li Shaowei
• Ge Shengxiang
• He Zhiqiang

Classifications

• A61P31/20

  for DNA viruses · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/14

  for RNA viruses · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title